Objective
The study of development and function of the immune system in vivo has made intensive use of animal models, but performing such work in human beings is difficult, for experimental, practical and ethical reasons.
Confronted to this scientific challenge, several pioneering groups have developed in the late 80s mouse models of human immune system development. The system has now been considerably improved with the Human Immune System (HIS) mouse that exhibits a complete human innate and adaptive immune system.
This new model is extremely suitable to test the response of the human immune system to candidate HIV vaccines in an in vivo setting. I propose in the present project to validate the HIS mice as a new model to study HIV vaccination. For infection, we will use a new promising strain, the HIV-rtTA, a conditional live-attenuated virus.
In this virus, the replication is controlled and dependent on the presence of a non-toxic effector molecule and thus can be turned on and off at will in a graded and reversible manner. This drug-dependent virus will provide a unique reagent to study the virus-host interaction and viral pathogenicity in vivo.
As a vaccination approach, one would like to limit virus replication to the extent that is needed to mount a protective immune response, after which replication is stopped and subsequent virus evolution is blocked.
The use of HIV-rtTA virus in the HIS mouse will provide relevant information on the requirements for a vaccine to obtain protection against HIV. Overall, this project will contribute to the validation of the HIS mouse model as a tool for pre-clinical tests.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology virology
- natural sciences biological sciences genetics mutation virus mutation
- medical and health sciences basic medicine immunology
- medical and health sciences health sciences infectious diseases viral diseases RNA viruses HIV
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2005-MOBILITY-5
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
AMSTERDAM
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.